UBS AM’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-135,804
| Closed | -$452K | – | 2527 |
|
|
2023
Q4 | $452K | Hold |
135,804
| – | – | ﹤0.01% | 2350 |
|
|
2023
Q3 | $508K | Buy |
135,804
+21,924
| +19% | +$101K | ﹤0.01% | 2291 |
|
|
2023
Q2 | $779K | Hold |
113,880
| – | – | ﹤0.01% | 2117 |
|
|
2023
Q1 | $779K | Buy |
113,880
+8,906
| +8% | +$69.1K | ﹤0.01% | 2117 |
|
|
2022
Q4 | $831K | Buy |
104,974
+48,472
| +86% | +$373K | ﹤0.01% | 1947 |
|
|
2022
Q3 | $543K | Sell |
56,502
-6,377
| -10% | -$64.5K | ﹤0.01% | 2312 |
|
|
2022
Q2 | $455K | Sell |
62,879
-16,032
| -20% | -$139K | ﹤0.01% | 2349 |
|
|
2022
Q1 | $1.02M | Hold |
78,911
| – | – | ﹤0.01% | 2128 |
|
|
2021
Q4 | $1.26M | Hold |
78,911
| – | – | ﹤0.01% | 2082 |
|
|
2021
Q3 | $1.27M | Hold |
78,911
| – | – | ﹤0.01% | 2039 |
|
|
2021
Q2 | $1.09M | Sell |
78,911
-132,538
| -63% | -$1.88M | ﹤0.01% | 2158 |
|
|
2021
Q1 | $3.09M | Sell |
211,449
-2,042,457
| -91% | -$34.7M | ﹤0.01% | 1567 |
|
|
2020
Q4 | $39.2M | Buy |
2,253,906
+555,584
| +33% | +$9.89M | 0.02% | 665 |
|
|
2020
Q3 | $31.1M | Sell |
1,698,322
-138,838
| -8% | -$2.58M | 0.02% | 646 |
|
|
2020
Q2 | $32.8M | Sell |
1,837,160
-22,017
| -1% | -$373K | 0.02% | 600 |
|
|
2020
Q1 | $30.2M | Sell |
1,859,177
-58,297
| -3% | -$1.08M | 0.02% | 586 |
|
|
2019
Q4 | $34.5M | Buy |
1,917,474
+346,993
| +22% | +$6.4M | 0.02% | 631 |
|
|
2019
Q3 | $31.8M | Buy |
1,570,481
+51,968
| +3% | +$1.04M | 0.02% | 649 |
|
|
2019
Q2 | $33.6M | Sell |
1,518,513
-53,377
| -3% | -$927K | 0.02% | 634 |
|
|
2019
Q1 | $21.4M | Buy |
1,571,890
+257,191
| +20% | +$3.43M | 0.02% | 727 |
|
|
2018
Q4 | $11.9M | Buy |
1,314,699
+52,862
| +4% | +$612K | 0.01% | 824 |
|
|
2018
Q3 | $20.8M | Sell |
1,261,837
-51,136
| -4% | -$906K | 0.02% | 743 |
|
|
2018
Q2 | $18.4M | Sell |
1,312,973
-8,297
| -0.6% | -$119K | 0.01% | 792 |
|
|
2018
Q1 | $14.6M | Sell |
1,321,270
-72,391
| -5% | -$792K | 0.01% | 827 |
|
|
2017
Q4 | $12.3M | Buy |
1,393,661
+72,710
| +6% | +$778K | 0.01% | 866 |
|
|
2017
Q3 | $17.6M | Sell |
1,320,951
-70,265
| -5% | -$929K | 0.02% | 756 |
|
|
2017
Q2 | $20M | Buy |
1,391,216
+490,899
| +55% | +$9.44M | 0.02% | 743 |
|
|
2017
Q1 | $19M | Buy |
900,317
+398,644
| +79% | +$9.81M | 0.02% | 729 |
|
|
2016
Q4 | $14.1M | Buy |
501,673
+482,828
| +2,562% | +$13.5M | 0.02% | 788 |
|
|
2016
Q3 | $504K | Buy |
+18,845
| New | +$514K | ﹤0.01% | 1976 |
|
|
2016
Q2 | – | Sell |
-9,567
| Closed | -$203K | – | 2613 |
|
|
2016
Q1 | $203K | Sell |
9,567
-1,932
| -17% | -$31.7K | ﹤0.01% | 2426 |
|
|
2015
Q4 | $264K | Buy |
+11,499
| New | +$296K | ﹤0.01% | 2399 |
|
Other funds holding CHRS
RCMNY
KKRC
UBS AM's CHRS Position: Q1 2024 in Review
UBS AM sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 135,804 shares — an estimated $452K sold.
UBS AM first reported a position in CHRS in Q4 2015 and held it in 32 quarters. The position peaked at $39.2M in Q4 2020. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.
- UBS AM reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
- UBS AM sold 135,804 Coherus Oncology shares in Q1 2024, an estimated $452K.
- UBS AM first reported a position in Coherus Oncology in Q4 2015 and held it in 32 quarters.
- UBS AM's Coherus Oncology position peaked at $39.2M in Q4 2020.
- 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.
Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.